Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

Author(s):
Schwartz, G.G.; Bessac, L.; Berdan, L.G.; Bhatt, D.L.; Bittner, V.; Diaz, R.; Goodman, S.G.; Hanotin, C.; Harrington, R.A.; Jukema, J.W. (0000-0002-3246-8359); Mahaffey, K.W.; Moryusef, A.; Pordy, R.; Roe, M.T.; Rorick, T.; Sasiela, W.J.; Shirodaria, C.; Szarek, M.; Tamby, J.F.; Tricoci, P.; White, H.; Zeiher, A.; Steg, P.G.
Published
2014
Publication type
Article / Letter to editor
Date issued
2014-11-30
Language
English
Is part of
American Heart Journal (2014), Vol. 168, no. 5, p. 682-689
hdl
1887/103261
doi
10.1016/j.ahj.2014.07.028